Proactis（0NTX）株式概要プロアクティスSAはソース・ツー・ペイのソフトウェア・ソリューションを提供している。 詳細0NTX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 株式の流動性は非常に低い 過去1年間で収益は11.9%減少しました 意味のある時価総額がありません ( €9M )すべてのリスクチェックを見る0NTX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.04975.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m31m2016201920222025202620282031Revenue €14.1mEarnings €1.7mAdvancedSet Fair ValueView all narrativesProactis SA 競合他社MobilityOneSymbol: AIM:MBOMarket cap: UK£8.8mShearwater GroupSymbol: AIM:SWGMarket cap: UK£9.3mt42 IoT Tracking SolutionsSymbol: AIM:TRACMarket cap: UK£3.3mCirataSymbol: AIM:CRTAMarket cap: UK£23.4m価格と性能株価の高値、安値、推移の概要Proactis過去の株価現在の株価€0.04952週高値€0.09352週安値€0.049ベータ0.711ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-90.20%最新ニュースお知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.お知らせ • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025お知らせ • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.お知らせ • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.お知らせ • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024最新情報をもっと見るRecent updatesお知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.お知らせ • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025お知らせ • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.お知らせ • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.お知らせ • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024Board Change • Apr 12No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Stephen Line is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Mar 21No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Stephen Line is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.株主還元0NTXGB SoftwareGB 市場7D0%0.7%-0.1%1Yn/a-26.3%18.0%株主還元を見る業界別リターン: 0NTXがUK Software業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 0NTX UK市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 0NTX's price volatile compared to industry and market?0NTX volatility0NTX Average Weekly Movementn/aSoftware Industry Average Movement5.7%Market Average Movement5.7%10% most volatile stocks in GB Market11.9%10% least volatile stocks in GB Market3.1%安定した株価: 0NTX 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間の0NTXのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1990125Stephen Linewww.proactis.comプロアクティスSAはソース・ツー・ペイのソフトウェア・ソリューションを提供している。業務支出を管理するソフトウェア・プラットフォームを運営している。また、日常的な商品・サービス、資本財、主要プロジェクトの購買プロセスに必要なツールを購買担当者に提供する調達ソリューションも提供している。さらに、請求書の取り込みサービス、システム管理、サプライヤーのオンボーディング、支出管理サービスも提供している。さらに、同社のソリューションは様々なERPや財務システムと統合している。同社は以前HUBWOOとして知られていたが、2019年1月にProactis SAに社名を変更した。同社はフランスのSuresnesを拠点としている。Proactis SAはProactis Euro Hedgeco Limitedの子会社として運営されている。もっと見るProactis SA 基礎のまとめProactis の収益と売上を時価総額と比較するとどうか。0NTX 基礎統計学時価総額€8.67m収益（TTM）-€634.00k売上高(TTM)€14.11m0.6xP/Sレシオ-13.7xPER（株価収益率0NTX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0NTX 損益計算書（TTM）収益€14.11m売上原価€12.22m売上総利益€1.89mその他の費用€2.53m収益-€634.00k直近の収益報告Jan 31, 2023次回決算日該当なし一株当たり利益（EPS）-0.0047グロス・マージン13.41%純利益率-4.49%有利子負債／自己資本比率0%0NTX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/09 06:48終値2024/04/11 00:00収益2023/01/31年間収益2022/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Proactis SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025
お知らせ • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.
お知らせ • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024
お知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025
お知らせ • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.
お知らせ • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024
Board Change • Apr 12No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Stephen Line is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Mar 21No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Stephen Line is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
